Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) EV/EBITDA
As of Nov 19, 2026, Eli Lilly and Company (LLY) trades at a EV/EBITDA of 33.9×. Over the past ten years it has ranged from 16.9× (December 2016) to 93.6× (October 2024); the current reading is higher than 71% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 8.5×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 35.3× | (28.22%) |
| FY2024 | 49.2× | (28.67%) |
| FY2023 | 69.0× | 73.88% |
| FY2022 | 39.7× | 19.01% |
| FY2021 | 33.3× | 48.09% |
| FY2020 | 22.5× | 3.21% |
| FY2019 | 21.8× | (7.08%) |
| FY2018 | 23.5× | (7.91%) |
| FY2017 | 25.5× | 49.17% |
| FY2016 | 17.1× | (24.37%) |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 29.2× | (6.44%) |
| Jun 2026 | 31.2× | 22.15% |
| Mar 2026 | 25.6× | (27.59%) |
| Dec 2025 | 35.3× | 21.99% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PFE Pfizer Inc. compare | 10.2× |
| AZN AstraZeneca PLC compare | 13.9× |
| NVS Novartis AG compare | 14.6× |
| AMGN Amgen Inc. compare | 16.2× |
| ABBV AbbVie Inc. compare | 19.8× |
| JNJ Johnson & Johnson compare | 23.9× |
| MRK Merck & Co., Inc. compare | 27.1× |
| LLY Eli Lilly and Company | 33.9× |
| GILD Gilead Sciences, Inc. compare | 502× |
| Drug Manufacturers General industry median | 13.9× |
| Healthcare sector median | 8.5× |
| Market median | 10.4× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement